Apimeds Pharmaceuticals US Inc
APUS1.645USD
-0.095-5.46%
Market hours （ET）Quotes delayed by 15 min
13.00MMarket Cap
LossP/E TTM
More Details of Apimeds Pharmaceuticals US Inc Company
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
Company Info
Ticker SymbolAPUS
Company nameApimeds Pharmaceuticals US Inc
IPO dateMay 09, 2025
CEOMr. Erik C. Emerson
Number of employees2
Security typeOrdinary Share
Fiscal year-endMay 09
Address100 Matawan Road
CityMATAWAN
Stock exchangeNYSE American Consolidated
CountryUnited States of America
Postal code07747
Phone18482015010
Websitehttps://www.apimedsus.com/
Ticker SymbolAPUS
IPO dateMay 09, 2025
CEOMr. Erik C. Emerson
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Erik C. Emerson
Mr. Erik C. Emerson
Chief Executive Officer, Director
Chief Executive Officer, Director
750.00K
--
Mr. Jakap Koo
Mr. Jakap Koo
Director
Director
643.88K
+4.63%
Dr. Christopher Kim, M.D.
Dr. Christopher Kim, M.D.
Chairman of the Board, Chief Medical Officer
Chairman of the Board, Chief Medical Officer
277.50K
--
Ms. Elona Kogan, Esq.
Ms. Elona Kogan, Esq.
Independent Director
Independent Director
--
--
Ms. Carol O'Donnell
Ms. Carol O'Donnell
Independent Director
Independent Director
--
--
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Independent Director
--
--
Dr. Hankil Yoon, Ph.D.
Dr. Hankil Yoon, Ph.D.
Independent Director
Independent Director
--
--
Mr. Erick Frim
Mr. Erick Frim
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Erik C. Emerson
Mr. Erik C. Emerson
Chief Executive Officer, Director
Chief Executive Officer, Director
750.00K
--
Mr. Jakap Koo
Mr. Jakap Koo
Director
Director
643.88K
+4.63%
Dr. Christopher Kim, M.D.
Dr. Christopher Kim, M.D.
Chairman of the Board, Chief Medical Officer
Chairman of the Board, Chief Medical Officer
277.50K
--
Ms. Elona Kogan, Esq.
Ms. Elona Kogan, Esq.
Independent Director
Independent Director
--
--
Ms. Carol O'Donnell
Ms. Carol O'Donnell
Independent Director
Independent Director
--
--
Dr. Bennett Weintraub, Ph.D.
Dr. Bennett Weintraub, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Apimeds, Inc.
37.90%
Inscobee, Inc.
17.52%
Dominus IB, Inc
6.91%
Emerson (Erik C)
6.48%
Koo (Jakap)
5.56%
Other
25.62%
Shareholders
Shareholders
Proportion
Apimeds, Inc.
37.90%
Inscobee, Inc.
17.52%
Dominus IB, Inc
6.91%
Emerson (Erik C)
6.48%
Koo (Jakap)
5.56%
Other
25.62%
Shareholder Types
Shareholders
Proportion
Corporation
67.52%
Individual Investor
14.44%
Other
18.04%
Institutional Shareholding
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
7
9.49M
81.96%
+7.39M
2025Q2
7
9.49M
81.96%
+7.39M
2025Q1
2
2.10M
18.15%
+2.10M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Apimeds, Inc.
4.39M
37.9%
+4.39M
--
May 12, 2025
Inscobee, Inc.
2.03M
17.52%
+544.04K
+36.65%
May 12, 2025
Dominus IB, Inc
800.00K
6.91%
+800.00K
--
May 09, 2025
Emerson (Erik C)
750.00K
6.48%
+750.00K
--
May 16, 2025
Koo (Jakap)
643.88K
5.56%
+28.50K
+4.63%
May 12, 2025
Seed 1 ho
600.00K
5.18%
+600.00K
--
May 09, 2025
Kim (Christopher)
277.50K
2.4%
+277.50K
--
May 16, 2025
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
